January 9, 2018 / 1:25 PM / a month ago

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

* INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION

* INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO‘S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below